Amgen’s deal to acquire a minority stake in Chinese oncology research firm BeiGene closed Jan. 2, with a $2.8 billion cash price tag. The deal includes rights to commercialize Amgen’s Xgeva, Kyprolis and Blincyto products in China, and an equal share of profits or losses in the first five years. At $174.85 per share, the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
